Select Medical's board and senior management are under investigation by Bleichmar Fonti & Auld LLP for possible breaches of fiduciary duties related to the company's pending sale at $16.50 per share. The deal, announced in March 2026, involves a consortium including company insiders who are allowed to retain shares post-merger, unlike public shareholders. The investigation questions the fairness of the merger process and disclosures ahead of a shareholder vote scheduled for June 26, 2026. Shareholders are encouraged to seek legal advice as the merger could close soon after the vote, limiting their options to challenge the deal.
Johnson Fistel, PLLP is investigating whether Select Medical Holdings' board breached fiduciary duties in the proposed $16.50 per share sale to a consortium led by company insiders and Welsh, Carson, Anderson & Stowe. The deal, expected to close mid-...
Kaskela Law is investigating the proposed $16.50 per share buyout of Select Medical Holdings Corp. announced in March 2026. The firm questions whether this price fairly compensates shareholders, noting at least one analyst had a $19 price target at t...
Bleichmar Fonti & Auld LLP is investigating Select Medical Holdings Corporation's board and senior management for possible breaches of fiduciary duty related to the company's pending sale at $16.50 per share. The acquisition involves insiders allowed...
